Zobrazeno 1 - 7
of 7
pro vyhledávání: ''
Publikováno v:
Journal for Immunotherapy of Cancer
In breast cancer, increased cyclooxygenase-2 expressions is associated with poor prognosis. COX-2 expression influences production of pro-inflammatory prostaglandins. The present study investigated association between COX-2 promoter polymorphisms (rs
Autor:
Sotirios P Fortis, Nikolaos Anastasopoulos, Constantin N. Baxevanis, Louisa G. Mahaira, Sonia A. Perez, Nectaria N. Sotiriadou, Michael Sofopoulos, Christopher Shipp, John F Voutsas, Niki Arnogiannaki, Christoforos Haritos, Graham Pawelec
Publikováno v:
Journal for Immunotherapy of Cancer
Meeting abstracts Recent studies linking immune signatures in cancer with prognosis have provided unequivocal proof of the essential role of the immune system in tumor pathophysiology. They have also initiated a quest for immune biomarkers that could
Autor:
Soheir Demian, Amal Sobhy El-Sedfy, Fadwa Mohammed Ahmedai, Ahmed Saad Ahmed, Mona Hamdy El-Sayed
Publikováno v:
Journal for Immunotherapy of Cancer
Breast cancer is the commonest malignancy of women in many parts of the world and comprises 18% of all female cancers. There is one million new cases in the world each year. Neopterin which is a pteridine produced by activation of monocytes by IFN-γ
Autor:
Michelle Kinnaird, Maggie DiNome, Peter Sieling, Yi Guo, Delphine J. Lee, Jaime Shamonki, Ingrid Cely, Alfred A. Chan, Begonya Comin-Anduix
Publikováno v:
Journal for Immunotherapy of Cancer
Meeting abstracts While current breast cancer staging includes lymph node involvement as a key indicator of prognosis, little is known about how healthy tissue surrounding the immediate tumor microenvironment contributes to the loco-regional spread o
Autor:
Ines Simeone, Davide Bedognetti, Halima Bensmail, Wouter Hendrickx, Michele Ceccarelli, Ena Wang, Francesco M. Marincola, Lance D. Miller
Publikováno v:
Journal for Immunotherapy of Cancer
Meeting abstracts Overlapping immune signatures are observed among cancers with a better prognostic connotation and those with an increased likelihood to respond to immunotherapeutic approaches [[1][1], [2][2]]. Such signatures qualitatively overlap
Autor:
A Tawfeek
Publikováno v:
Journal for Immunotherapy of Cancer
Meeting abstracts Tamoxifen has been a standard adjuvant hormonal treatment for estrogen receptor ER positive breast cancer, both in pre and postmenopausal women. It has been noticed that some breast cancer patients don’t respond to tamoxifen as ot
Epirubicin sequential natural killer cells enhanced the cytotoxicity to breast cancer cells in vitro
Publikováno v:
Journal for Immunotherapy of Cancer
Meeting abstracts Anthracycline-based chemotherapy is a conventional therapy for breast cancer patients, but also negatively affects host immune function. When the host immune system does not work, chemotherapy and radiotherapy cannot kill the cancer